Phase I Dose-Escalation Results for Marizomib in Newly Diagnosed Glioblastoma

Daniela Bota, MD

Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.

Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.

According to the results, marizomib is a well-tolerated drug amongst patients with newly diagnosed glioblastoma. The recommended dose identified in this trial was 0.8 mg/m2. The drug will be administered at days 1, 8, and 15 in a 28-day cycle, Bota explains.